ABIVAX Provides Corporate Update and Reports 2016 Half Year Financial Results
ABIVAX Provides Corporate Update and Reports 2016 Half Year Financial Results
September 20, 2016
ABIVAX Provides Corporate Update and Reports 2016 Half Year Financial Results
- ABX464 second Phase IIa (HIV/AIDS) on track, top line data expected before year end 2016
- Lead compoundagainst Chikungunya identified using ABIVAX’ proprietary anti-viral platform
- Lead compound against Ebola identified using ABIVAX’ polyclonal antibody technology platforms
- Robust cash position (28,1 M€) expected to cover ABIVAX’financial needs at least until the end of 2017
Paris, September 20th 2016 - ABIVAX (Euronext Paris : FR0012333284 – ABVX), an innovative biotechnology company targeting the immune system to eliminate viral disease , today provides a corporate update and reports its half-year financial results as of June 30 2016. The half-year financial report is available on the company’s website (Investors – Financial Reports). In compliance with regulations, the half-year financial results were reviewed, on a limited basis, by the company’s statutory auditors and were approved by ABIVAX’s Board of Directors on September 19th.